Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares IssuedShort-Term Debt repayments
Ratios

BeOne Medicines (BEIGF) EBIAT (2016 - 2025)

BeOne Medicines (BEIGF) has disclosed EBIAT for 11 consecutive years, with $66.5 million as the latest value for Q4 2025.

  • Quarterly EBIAT rose 143.79% to $66.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $286.9 million through Dec 2025, up 144.5% year-over-year, with the annual reading at $286.9 million for FY2025, 144.5% up from the prior year.
  • EBIAT for Q4 2025 was $66.5 million at BeOne Medicines, down from $124.8 million in the prior quarter.
  • The five-year high for EBIAT was $215.4 million in Q3 2023, with the low at -$590.7 million in Q4 2021.
  • Average EBIAT over 5 years is -$234.3 million, with a median of -$299.8 million recorded in 2023.
  • The sharpest move saw EBIAT plummeted 754.48% in 2022, then soared 202.88% in 2025.
  • Over 5 years, EBIAT stood at -$590.7 million in 2021, then increased by 24.61% to -$445.3 million in 2022, then grew by 17.47% to -$367.6 million in 2023, then soared by 58.68% to -$151.9 million in 2024, then soared by 143.79% to $66.5 million in 2025.
  • According to Business Quant data, EBIAT over the past three periods came in at $66.5 million, $124.8 million, and $94.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.